UNSPSC 51352424: Ethinyl estradiol/fluoxymesterone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS900. This VA Drug Class (HS900) classifies this compound as belonging to the group HORMONES/SYNTHETICS/MODIFIERS, OTHER.

UNSPSC 51352424 Ethinyl estradiol/fluoxymesterone is a Commodity code covering a specific pharmaceutical combination product. State and local procurement under this code reflects broader demand for generic and branded pharmaceuticals within Medicaid, state employee health plans, and multistate cooperative purchasing networks. The issuing bodies are typically state health and human services departments, state purchasing offices administering multistate cooperatives, and health plan administrators operating on behalf of state and local government entities. Work solicited includes supply of finished pharmaceutical products meeting FDA requirements, cGMP certification, and Drug Supply Chain Security Act compliance, with vendors required to maintain relationships with authorized pharmaceutical wholesalers and submit detailed product and pricing information via established procurement systems.

Recent activity centers on Minnesota and Texas. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon; the response deadline was March 26, 2026, with contract effectiveness set for July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for a proposed Therapeutic Pharmacy Initiative, signaling emerging state interest in alternative pharmaceutical supply models outside traditional pharmacy benefit manager and group purchasing organization channels. Both solicitations require vendor compliance with insurance, manufacturing, and product-quality standards; the MMCAP RFP weights price competitiveness at 75 percent and requires vendors to pay a 3 percent administrative fee on all purchases.